文献速递心境障碍

裸盖菇素辅助治疗对重性抑郁障碍的随机临床试验

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

该随机等待列表对照试验纳入27例未服抗抑郁药的重性抑郁障碍成人,评估裸盖菇素辅助心理治疗的效果。完成干预的24例中,立即治疗组第1周和第4周的GRID-HAMD评分显著低于延迟治疗组对应时间点,效应量大,部分患者达到应答和缓解。

要点

  • 裸盖菇素辅助心理治疗可快速显著降低抑郁严重度。
  • 第1周和第4周效应量大(Cohen d分别为2.5和2.6)。
  • 总体样本中第1周和第4周分别有71%达到临床应答。

核心结论

  • 裸盖菇素联合心理治疗对重性抑郁障碍具有疗效,支持进一步研究。

研究设计与样本

  • 随机等待列表对照临床试验,在美国约翰霍普金斯湾景医学中心进行。
  • 纳入21至75岁重性抑郁障碍成人,当前未使用抗抑郁药,无精神病性障碍、严重自杀尝试或住院史。
  • 27例随机分为立即治疗组(n=15)和延迟治疗组(等待列表对照,n=12)。
  • 干预为两次裸盖菇素给药(第1次20 mg/70 kg,第2次30 mg/70 kg)联合约11小时支持性心理治疗。
  • 主要结局为GRID-HAMD评分,基线要求≥17分,评估第1周和第4周(对应延迟组第5周和第8周)。

主要发现

  • 完成干预的24例中,立即治疗组第1周和第4周GRID-HAMD平均(SD)评分分别为8.0(7.1)和8.5(5.7),显著低于延迟组对应时间点的23.8(5.4)和23.5(6.0)。
  • 第5周效应量Cohen d=2.5(95%CI 1.4-3.5,P<.001),第8周Cohen d=2.6(95%CI 1.5-3.7,P<.001)。
  • QIDS-SR显示第1次给药后第1天抑郁评分从基线16.7(3.5)快速降至6.3(4.4)(Cohen d=2.6,95%CI 1.8-3.5,P<.001),并持续至第4周随访6.0(5.7)(Cohen d=2.3,95%CI 1.5-3.0,P<.001)。
  • 总体样本中,第1周和第4周分别有17例(71%)达到临床应答(GRID-HAMD评分降低≥50%)。
  • 总体样本中,第1周有14例(58%)、第4周有13例(54%)达到缓解(GRID-HAMD评分≤7)。

关键数值与推荐

  • 入组要求基线GRID-HAMD评分≥17分。
  • 两次裸盖菇素剂量分别为20 mg/70 kg和30 mg/70 kg。
  • 临床应答定义为GRID-HAMD评分降低≥50%,缓解定义为GRID-HAMD评分≤7。
  • 心理治疗总时长约11小时。

临床怎么用

  • 对于无精神病性障碍史、无严重自杀尝试史且未服抗抑郁药的重性抑郁障碍成人,裸盖菇素辅助心理治疗可能快速改善抑郁症状。
  • 治疗需在支持性心理治疗背景下进行,并密切监测近期和远期疗效。

局限性

  • 样本量小(27例随机,24例完成干预)。
  • 采用等待列表对照而非安慰剂对照,可能影响盲法和效应估计。
  • 随访时间较短(至第4周),长期疗效未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE: To investigate the effect of psilocybin therapy in patients with MDD. DESIGN, SETTING, AND PARTICIPANTS: This randomized, waiting list-controlled clinical trial was conducted at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. Adults aged 21 to 75 years with an MDD diagnosis, not currently using antidepressant medications, and without histories of psychotic disorder, serious suicide attempt, or hospitalization were eligible to participate. Enrollment occurred between August 2017 and April 2019, and the 4-week primary outcome assessments were completed in July 2019. A total of 27 participants were randomized to an immediate treatment condition group (n = 15) or delayed treatment condition group (waiting list control condition; n = 12). Data analysis was conducted from July 1, 2019, to July 31, 2020, and included participants who completed the intervention (evaluable population). INTERVENTIONS: Two psilocybin sessions (session 1: 20 mg/70 kg; session 2: 30 mg/70 kg) were given (administered in opaque gelatin capsules with approximately 100 mL of water) in the context of supportive psychotherapy (approximately 11 hours). Participants were randomized to begin treatment immediately or after an 8-week delay. MAIN OUTCOMES AND MEASURES: The primary outcome, depression severity was assessed with the GRID-Hamilton Depression Rating Scale (GRID-HAMD) scores at baseline (score of ≥17 required for enrollment) and weeks 5 and 8 after enrollment for the delayed treatment group, which corresponded to weeks 1 and 4 after the intervention for the immediate treatment group. Secondary outcomes included the Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR). RESULTS: Of the randomized participants, 24 of 27 (89%) completed the intervention and the week 1 and week 4 postsession assessments. This population had a mean (SD) age of 39.8 (12.2) years, was composed of 16 women (67%), and had a mean (SD) baseline GRID-HAMD score of 22.8 (3.9). The mean (SD) GRID-HAMD scores at weeks 1 and 4 (8.0 [7.1] and 8.5 [5.7]) in the immediate treatment group were statistically significantly lower than the scores at the comparable time points of weeks 5 and 8 (23.8 [5.4] and 23.5 [6.0]) in the delayed treatment group. The effect sizes were large at week 5 (Cohen d = 2.5; 95% CI, 1.4-3.5; P < .001) and week 8 (Cohen d = 2.6; 95% CI, 1.5-3.7; P < .001). The QIDS-SR documented a rapid decrease in mean (SD) depression score from baseline to day 1 after session 1 (16.7 [3.5] vs 6.3 [4.4]; Cohen d = 2.6; 95% CI, 1.8-3.5; P < .001), which remained statistically significantly reduced through the week 4 follow-up (6.0 [5.7]; Cohen d = 2.3; 95% CI, 1.5-3.0; P < .001). In the overall sample, 17 participants (71%) at week 1 and 17 (71%) at week 4 had a clinically significant response to the intervention (≥50% reduction in GRID-HAMD score), and 14 participants (58%) at week 1 and 13 participants (54%) at week 4 were in remission (≤7 GRID-HAMD score). CONCLUSIONS AND RELEVANCE: Findings suggest that psilocybin with therapy is efficacious in treating MDD, thus extending the results of previous studies of this intervention in patients with cancer and depression and of a nonrandomized study in patients with treatment-resistant depression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03181529.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021. PMID: 33146667. doi:10.1001/jamapsychiatry.2020.3285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。